Drugs / SARS-CoV-2 Vaccine (Vero Cells), Inactivated
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05003479 | Aug 2021 → Sep 2022 | COVID-19 | Shenzhen Kangtai Biological Products Co., LTD | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05003466 | Sep 2021 → Mar 2023 | COVID-19 | Shenzhen Kangtai Biological Products Co., LTD | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04852705 | May → Nov 2021 | COVID-19 | Shenzhen Kangtai Biological Products Co., LTD | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 Vaccine (Vero Cells), Inactivated | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05003466 ↗ |
| Known as | KCONVAC | “randomized in 3:1 ratio to receive 2 doses of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine, KCONVAC or placebo.” PMID 37967148 ↗ Sep 2023 |
| Modality | Vaccine | “SARS-CoV-2 Vaccine (Vero Cells), Inactivated” NCT04852705 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT04852705 ↗ |